Displaying drugs 11326 - 11350 of 11488 in total
Ciglitazone
Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.
Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market....
Experimental
Matched Description: … Ciglitazone is a potent and selective PPARγ ligand with an EC50 of 3.0 µM. ... Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones …
Carphenazine
Carphenazine is an antipsychotic drug, used in hospitalized patients in the management of chronic schizophrenic psychoses.
Withdrawn
Trafermin
Investigational
ZEN-012
ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II inhibition. ZEN-012 also expresses additional modes of action such as pro-apoptotic and anti-angiogenic properties. It is developed for the treatment of solid tumors.
Investigational
Matched Description: … ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms …
4-Phenylfentanyl
4-Phenylfentanyl is a sythetic opioid derived from fentanyl. 4-Phenylfentanyl is around 8x the potency of fentanyl in analgesic tests on animals, but more complex 4-heteroaryl derivatives such as substituted thiophenes and thiazoles are more potent still, as they are closer bioisosteres to the 4-carbomethoxy group of carfentanil.
Illicit
Matched Description: … 4-Phenylfentanyl is a sythetic opioid derived from fentanyl. 4-Phenylfentanyl is around 8x the potency …
Natural Killer Cell
Natural Killer (NK) cells originate and differentiate from hematopoietic stem cells through various signalling pathways involving cytokines and interleukins. These cells arise from CD34+ lymphoid progenitors and comprise 10-15% of all lymphocytes in human peripheral blood. Once completely differentiated, NK cells lack B (CD19-) and T(CD3-) lymphocyte markers and carry...
Investigational
Matched Description: … leukapheresis: a technique where immune cells are separated from red blood cells. ... The most standard and utilized source of NK cells is directly from the peripheral blood of a donor through ... stem cells (iPSCs) and human embryonic stem cells (HESCs) are also used to generate NK cells through a …
Medical Cannabis
The use of the plant species Cannabis sativa and Cannabis indica, popularly known as marijuana, has gained popularity in recent years for the management of a wide variety of medical conditions as a wave of legalization in North America has changed public and medical opinion on its use. Consequently, an...
Experimental
Investigational
Matched Description: … THC and CBD are converted from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic ... for such a wide variety of medical conditions. ... indica_, popularly known as marijuana, has gained popularity in recent years for the management of a …
TA-NIC
TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients. It is designed to raise anti-nicotine antibodies which bind to nicotine molecules in the patient's blood stream, reducing the rate and quantity of nicotine entry into the brain, to reduce the addictive...
Investigational
Matched Description: … TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients …
PMI-001
PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc. It is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis, lupus erythematosus and psoriasis.
Investigational
Matched Description: … PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics …
Iproclozide
Iproclozide is an irreversible and selective hydrazine class based monoamine oxidase inhibitor (MAOI). Although it was employed as an antidepressant for a time, the fact that the agent is capable of causing fulminant hepatitis and that its use has been documented as the cause for at least three reported fatalities...
Withdrawn
Matched Description: … Although it was employed as an antidepressant for a time, the fact that the agent is capable of causing …
Marimastat
Used in the treatment of cancer, Marmiastat is an angiogenesis and metastasis inhibitor. As an angiogenesis inhibitor it limits the growth and production of blood vessels. As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes.
Investigational
CAD106
CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.
Investigational
ETC-588
ETC-588, or LUV (large unilamellar vesicles), is made of naturally occurring lipids that circulate through arteries to facilitate the role of high-density lipoprotein (HDL) in removing accumulated cholesterol and other lipids from cells including those in the arterial wall. LUV are capable of transporting excess cholesterol from the vasculature to...
Investigational
Matched Description: … Esperion is currently developing ETC-588 as a treatment for patients with acute coronary syndromes. …
Cositecan
Cositecan is the novel camptothecin derivative which is also known as Karenitecin. It has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer.
Investigational
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine
25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist. It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion . It was discovered in 2014 at the University of Copenhagen.
Experimental
Matched Description: … 25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective …
Satraplatin
Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.
Investigational
Matched Description: … Satraplatin is a platinum compound that is currently under investigation as one treatment of patients …
Cosfroviximab
Investigational
Sodium chlorite
Used as an agent for cleaning drinking water. It is also used as an additive in products like toothpaste and mouthwash. Acidified sodium chlorite was approved by the U.S. Food and Drug Administration as of 2004, as an anti-microbial agent which is non-toxic, but not as a drug [A174811, L5413].
Experimental
Matched Description: … Food and Drug Administration as of 2004, as an anti-microbial agent which is non-toxic, but not as a …
Indisulam
Investigational
LGD-1550
LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.
Investigational
NS-3728
NS3728 is an orally active chloride channel blocker for the treatment of cancer.
Investigational
Besifovir dipivoxil
Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of RNA. Besifovir dipivoxil is believed to inhibit viral proliferation by interrupting the replicating machinery of the virus.
Investigational
Matched Description: … Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. …
Bisegliptin
Bisegliptin is a compound for the treatment of type 2 diabetes. It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion and lowering blood glucose levels without hypoglycemic effects.
Investigational
Matched Description: … Bisegliptin is a compound for the treatment of type 2 diabetes. …
Displaying drugs 11326 - 11350 of 11488 in total